FDA/CDC

FDA to recommend limits on heavy metals in baby foods


 

The Food and Drug Administration has responded to congressional criticism and launched a multiyear plan to reduce the amount of heavy metals such as mercury and arsenic found in baby food.

Catherine Delahaye/DigitalVision/Getty Images

Called “Closer to Zero,” the FDA plan calls for continued scientific investigation, establishes acceptable levels of heavy metals, sets up a way to monitor manufacturers’ compliance, and sets “action levels.”

“Although the FDA’s testing shows that children are not at an immediate health risk from exposure to toxic elements at the levels found in foods, we are starting the plan’s work immediately, with both short- and long-term goals for achieving continued improvements in reducing levels of toxic elements in these foods over time,” the FDA said.

However, Closer to Zero will only make recommendations on heavy metal levels.

“Although action levels are not binding, we have seen that, over the years, our guidance on action levels and other actions have contributed to significant reductions of toxic elements in food,” an FDA spokeswoman wrote in a statement, according to the Washington Post.

A congressional panel said in February 2021 that major brands of commercial baby food routinely have high levels of toxic heavy metals. The House Oversight Committee said this leaves babies at risk for serious developmental and neurologic problems.

The committee sharply criticized the FDA for not taking action.

“Despite the well-known risks of harm to babies from toxic heavy metals, FDA has not taken adequate steps to decrease their presence in baby foods,” the committee said. “FDA has not issued thresholds for the vast majority of toxic heavy metals in baby foods and does not require warning labels on any baby food products.”

A version of this article first appeared on WebMD.com.

Recommended Reading

Registry reveals H. pylori management mistakes
Journal of Clinical Outcomes Management
Pharmacists’ Bleed Risk Tool and Treatment Preferences Prior to Initiating Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Cross-Sectional Survey
Journal of Clinical Outcomes Management
Defining wellness in IBD
Journal of Clinical Outcomes Management
High cost of pancreatic enzymes a barrier for patients with cancer
Journal of Clinical Outcomes Management
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)
Journal of Clinical Outcomes Management
AGA Clinical Practice Update: Bariatric surgery in patients with cirrhosis
Journal of Clinical Outcomes Management
ACG: CRC screening should start at age 45
Journal of Clinical Outcomes Management
Researchers stress importance of second COVID-19 vaccine dose for infliximab users
Journal of Clinical Outcomes Management
Low-risk adenomas may not elevate risk of CRC-related death
Journal of Clinical Outcomes Management
FDA approves first AI device to detect colon lesions
Journal of Clinical Outcomes Management